Key Takeaways:
Eli Lilly's next-generation obesity drug, retatrutide, demonstrated superior weight loss in Phase 3 trials, positioning it to potentially overtake its own drug Zepbound and rival Novo Nordisk's Wegovy.
"With retatrutide, Eli Lilly aims to bring to market a '''triple agonist,''' targeting GLP-1 and GIP receptors, as well as glucagon receptors," a recent market analysis noted, highlighting its advantage over dual-agonist Zepbound and single-agonist Wegovy.
In trials unveiled in March, retatrutide led to significant reductions in A1C and body weight. This comes as Lilly's current market leader Zepbound holds a 59.5% market share with nearly 656,000 weekly prescriptions, compared to Wegovy's 40.5% share and 446,000 scripts, according to IQVIA data.
The development could further cement Eli Lilly's dominance in the highly lucrative weight-loss market. While retatrutide is still months from launch, its high commercial potential is a key factor supporting LLY's premium valuation of over 26 times forward earnings.
The key innovation behind retatrutide is its ability to target three distinct hormone receptors. While Novo Nordisk's Wegovy is a single-agonist drug targeting only GLP-1, and Lilly's own Zepbound is a dual-agonist hitting GLP-1 and GIP receptors, retatrutide adds a third target: glucagon receptors. This triple-action mechanism is believed to lead to greater overall weight loss and improved metabolic control. While Lilly is advancing its triple-agonist candidate, Novo Nordisk is still in the process of developing its own dual-agonist product.
The battle for market supremacy is also being fought on the convenience front, with both companies recently launching oral versions of their GLP-1 drugs. For the week ended May 8, prescriptions for Eli Lilly’s oral drug Foundayo reached 10,248. This trails the roughly 137,000 weekly scripts for Novo Nordisk's Wegovy pill, which had a three-month head start. However, analysts point to a key convenience advantage for Lilly's Foundayo: it can be taken with or without food, unlike the Wegovy pill which requires fasting. This may make it a preferred option for long-term weight maintenance.
The promising results for retatrutide suggest Eli Lilly may be poised to extend its lead in the highly competitive obesity market. Investors will be closely watching for the full data presentation and the company's timeline for filing for FDA approval.
This article is for informational purposes only and does not constitute investment advice.
